000538 Yunnan Baiyao Group
- 55.94
- -0.32-0.57%
Yunnan Baiyao Group News
Yunnan Baiyao to Conduct Clinical Trials on Flurbiprofen Gel Patch
Yunnan Baiyao Group (SHE:000538) will conduct clinical trials on flurbiprofen gel patch after receiving approval from China's National Medical Products Administration, the company said in a Saturday d
Yunnan Baiyao (000538.SZ): INR101 injection approved for drug clinical trials
Gelonghui, May 10 | Yunnan Baiyao (000538.SZ) announced that Yunhe Pharmaceutical (Tianjin) Co., Ltd. (“Yunhe Pharmaceutical”), a wholly-owned subsidiary of the company, recently received the “Drug Clinical Trial Approval Notice” (Notice No.: 2024LP01109) issued by the State Drug Administration. After review, Yunhe Pharmaceutical's INR101 injection (hereinafter referred to as “this product”) clinical trial application met the relevant requirements for drug registration and agreed to conduct clinical trials on healthy people and prostate cancer. This product is an innovative chemical class 1 radiological diagnostic drug developed by Yunnuclear Pharmaceutical. It is suitable for the past
Why It Might Not Make Sense To Buy Yunnan Baiyao Group Co.,Ltd (SZSE:000538) For Its Upcoming Dividend
Readers hoping to buy Yunnan Baiyao Group Co.,Ltd (SZSE:000538) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is one business
Gelonghui Announcements Selected | Mindray Healthcare: Net profit increased 22.9% to 3.16 billion yuan in the first quarter, and all three major international business lines achieved rapid growth; Yunnan Baiyao: Net profit of 1.702 billion yuan in the fir
[Performance data] Sanan Optoelectronics (600703.SH): Net profit of 367 million yuan in 2023, and plans to distribute 0.3 yuan Sanan Optoelectronics (600703.SH) to release the 2023 annual report, achieving operating income of 14.53 billion yuan, an increase of 6.28%; net profit attributable to shareholders of listed companies was 367 million yuan, a year-on-year decrease of 46.50%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - $1,088 million, with basic earnings per share of 0.07 yuan. It is proposed to distribute a cash dividend of 0.30 yuan (tax included) for every 10 shares to all shareholders. Changsha silver
Research Report Nuggets丨Guotai Junan: Yunnan Baiyao's 23-year performance is in line with expectations and maintains an “gain” rating
According to the Guotai Junan Research Report, Yunnan Baiyao (000538.SZ)'s 23-year performance was in line with expectations. The core variety of Baiyao drugs and health products continued to grow at a high rate. Although profit disturbances in 23Q4 were obvious, overall disruptive factors decreased significantly, and the dividend ratio continued to be high, demonstrating confidence in future development. Maintain the target price of 63.36 yuan and the “Overweight” rating. The 23-year dividend plan is a dividend of 20.77 yuan for every 10 shares, with a total dividend of 3.706 billion yuan, accounting for 90.53% of net profit attributable to mother. The dividend ratio has continued to exceed 90% in the past two years.
Yunnan Baiyao GroupLtd (SZSE:000538) Shareholders Have Endured a 36% Loss From Investing in the Stock Three Years Ago
As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand at stock picking, your risk returning less than the market. We regret to report
Yunnan Baiyao Group's Profit Rises 30% as Operating Income Increases
Yunnan Baiyao Group's (SHE:000538) attributable profit rose 30.47% to 4.09 billion yuan in 2023 from 3 billion yuan in 2022, according to a Monday filing with the Shenzhen bourse. Earnings per share a
Is Yunnan Baiyao Group Co.,Ltd's (SZSE:000538) Recent Stock Performance Influenced By Its Financials In Any Way?
Most readers would already know that Yunnan Baiyao GroupLtd's (SZSE:000538) stock increased by 5.1% over the past three months. Given that stock prices are usually aligned with a company's financial
Yunnan Baiyao (000538.SZ): Issuing 3 billion yuan of ultra-short-term financing notes approved for registration
Gelonghui, Feb. 27丨Yunnan Baiyao (000538.SZ) announced that on February 26, 2024, the company received the “Notice of Acceptance of Registration” (China Market Association Note (2024) SCP63) from the Dealers Association and agreed to accept the registration of the company's ultra-short-term financing notes. According to the “Notice of Acceptance of Registration” mentioned above, the registration amount of the company's ultra-short-term financing notes is 3 billion yuan. The registration amount is valid for 2 years from the date of payment of the notice and is underwritten by Industrial and Commercial Bank of China Co., Ltd.; the company can issue ultra-short-term financing notes in installments during the registration period, and after the issuance is completed, they will be approved by the Dealers Association
Investors Don't See Light At End Of Yunnan Baiyao Group Co.,Ltd's (SZSE:000538) Tunnel
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 29x, you may consider Yunnan Baiyao Group Co.,Ltd (SZSE:000538) as an attractive investment with its 18.5x P/
Yunnan Baiyao Group Co.,Ltd (SZSE:000538) Shares Could Be 35% Above Their Intrinsic Value Estimate
Key Insights The projected fair value for Yunnan Baiyao GroupLtd is CN¥34.56 based on Dividend Discount Model Current share price of CN¥46.51 suggests Yunnan Baiyao GroupLtd is potentially 35% overv
When Yunnan Baiyao quit gambling
It's very stressful
Jiangsu Yuyue, a shareholder of Yunnan Baiyao (000538.SZ), completed a total reduction of 359.366 million shares
Yunnan Baiyao (000538.SZ) announced that the company's shareholder Jiangsu Yuyue's holdings reduction plan has expired, and Jiangsu Yuyue has completed...
Yunnan Baiyao GroupLtd (SZSE:000538) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Yunnan Baiyao (000538.SZ): Currently, there are no drugs specifically used to treat mycoplasma infections
Glonghui, December 22|An investor asked Yunnan Baiyao (000538.SZ) on the investor interactive platform, “Does the company produce drugs to treat mycoplasma pneumonia?” The company replied that currently the company has no drugs specifically used to treat mycoplasma infections.
Shanghai Pharma, Yunnan Baiyao Renew Sales, Procurement Deal
Shanghai Pharmaceuticals Holding (HKG:2607, SHA:601607) will continue trading products and services with Yunnan Baiyao Group (SHE:000538) after both parties renewed their sales and procurement framewo
Declining Stock and Decent Financials: Is The Market Wrong About Yunnan Baiyao Group Co.,Ltd (SZSE:000538)?
It is hard to get excited after looking at Yunnan Baiyao GroupLtd's (SZSE:000538) recent performance, when its stock has declined 8.9% over the past three months. But if you pay close attention, you
Shareholders in Yunnan Baiyao GroupLtd (SZSE:000538) Are in the Red If They Invested Three Years Ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But in any portfolio, there are likely to be some stocks that fall sho
Yunnan Baiyao (000538.SZ): In the first half of the year, Yunnan Baiyao aerosol contributed more than 900 million yuan in revenue, an increase of 18.20% over the previous year
Gelonghui November 2 | Yunnan Baiyao (000538.SZ) was surveyed by specific subjects on October 31, 2023. Regarding “Please tell me about the sales situation of Yunnan Baiyao core series products and other brands of traditional Chinese medicine in the first half of the year”, the company replied that in the first half of 2023, Yunnan Baiyao Aerosol contributed more than 900 million yuan in revenue, an increase of 18.20% over the previous year; the revenue of Yunnan Baiyao Cream and Yunnan Baiyao capsules continued to grow. In terms of other brands of traditional Chinese medicine products, seizing market expansion opportunities, the business and OTC sectors have expanded and increased the scope of multiple products through medium output and product-driven methods. Cold-like products
Yunnan Baiyao's Profit Jumps 61% in Q3 as Revenue Rises 5%
Yunnan Baiyao Group (SHE:000538) posted a 61.1% year-over-year jump in net profit in the third quarter of the year as revenue rose 5.4% from a year earlier. Net profit stood at 1.3 billion yuan, or 0.
Analysis
Price Target
No Data
